Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab

Authors

  • Luigi Gargiulo Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI); Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Francesco Toso Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI); Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Luciano Ibba Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI); Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Mario Valenti Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI); Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Antonio Costanzo Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI); Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy
  • Alessandra Narcici Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano (MI); Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Italy

Keywords:

psoriasis, acrodermatitis continua of Hallopeau, ixekizumab, ustekinumab, biologics

References

Navarini AA, Burden AD, Capon F, et al. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792-1799. doi:10.1111/jdv.14386

Maliyar K, Crowley EL, Rodriguez-Bolanos F, O'Toole A, Gooderham MJ. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review. J Cutan Med Surg. 2019;23(4):428-435. doi:10.1177/1203475419836435

Miller AC, Holland TE, Cohen DJ. Treatment of acrodermatitis continua of hallopeau with ixekizumab. J Dermatolog Treat. 2021;32(1):117-119. doi:10.1080/09546634.2019.1628170

Narcisi A, Valenti M, Cortese A, et al. Anti-IL17 and anti-IL23 biologic drugs for scalp psoriasis: A single-center retrospective comparative study. Dermatol Ther. 2022;35(2):e15228. doi:10.1111/dth.15228

Husson B, Barbe C, Hegazy S, et al. Efficacy and safety of TNF blockers and of ustekinumab in palmoplantar pustulosis and in acrodermatitis continua of Hallopeau. J Eur Acad Dermatol Venereol. 2020;34(10):2330-2338. doi:10.1111/jdv.16265

Gargiulo L, Pavia G, Ibba L, et al. Generalized Pustular Psoriasis and Plaque Psoriasis Successfully Treated With Ixekizumab. Clin Exp Dermatol Ther. 2022; 7: 183. doi: 10.29011/2575-8268.100183. Published online ahead of print.

Downloads

Published

2023-04-29

Issue

Vol. 13 No. 2 (2023): 2023 Vol 13, No 2 | April

Section

Research Letter

License

Copyright (c) 2023 Luigi Gargiulo, Francesco Toso, Luciano Ibba, Mario Valenti, Antonio Costanzo, Alessandra Narcici

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.

How to Cite

1.
Gargiulo L, Toso F, Ibba L, Valenti M, Costanzo A, Narcici A. Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab . Dermatol Pract Concept. 2023;13(2):e2023103. doi:10.5826/dpc.1302a103

Share

Crossref
Scopus
Google Scholar
Europe PMC